(Q46450711)

22 December 2017

title

Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis (English)

1 reference

22 December 2017

1 reference

10

Bradley P Carlin

1 reference

22 December 2017

author name string

David Ohlssen

1

1 reference

22 December 2017

Karen L Price

2

1 reference

22 December 2017

H Amy Xia

3

1 reference

22 December 2017

Hwanhee Hong

4

1 reference

22 December 2017

Jouni Kerman

5

1 reference

22 December 2017

Haoda Fu

6

1 reference

22 December 2017

George Quartey

7

1 reference

22 December 2017

Cory R Heilmann

8

1 reference

22 December 2017

Haijun Ma

9

1 reference

22 December 2017

publication date

30 August 2013

1 reference

22 December 2017

Pharmaceutical Statistics

published in

1 reference

22 December 2017

volume

13

1 reference

22 December 2017

issue

1

1 reference

22 December 2017

page(s)

55-70

1 reference

22 December 2017

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

cites work

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

21 January 2018

1 reference

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.

21 January 2018

1 reference

Bayesian measures of model complexity and fit

21 January 2018

1 reference

Meta-analysis for 2 x 2 tables: a Bayesian approach

21 January 2018

1 reference

Bayesian approaches to random-effects meta-analysis: a comparative study.

21 January 2018

1 reference

A re-evaluation of random-effects meta-analysis.

21 January 2018

1 reference

Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales

21 January 2018

1 reference

How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS.

21 January 2018

1 reference

Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews

21 January 2018

1 reference

Meta-analysis of individual- and aggregate-level data.

21 January 2018

1 reference

Bias modelling in evidence synthesis

21 January 2018

1 reference

Meta-analysis using Dirichlet process

21 January 2018

1 reference

Bayesian models for subgroup analysis in clinical trials.

21 January 2018

1 reference

Meta-analysis for the evaluation of potential surrogate markers.

21 January 2018

1 reference

A practical introduction to multivariate meta-analysis.

21 January 2018

1 reference

Modeling between-trial variance structure in mixed treatment comparisons

21 January 2018

1 reference

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

21 January 2018

1 reference

Statistical approaches for conducting network meta-analysis in drug development.

21 January 2018

1 reference

The use of two-way linear mixed models in multitreatment meta-analysis

21 January 2018

1 reference

Evaluation of networks of randomized trials

21 January 2018

1 reference

Comparing Bayesian and frequentist approaches for multiple outcome mixed treatment comparisons.

21 January 2018

1 reference

Summarizing historical information on controls in clinical trials

21 January 2018

1 reference

Structured approach to the elicitation of expert beliefs for a Bayesian-designed clinical trial: a case study

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study

21 January 2018

1 reference

The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials

21 January 2018

1 reference

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

21 January 2018

1 reference

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

21 January 2018

1 reference

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

21 January 2018

1 reference

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

21 January 2018

1 reference

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

21 January 2018

1 reference

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies

21 January 2018

1 reference

Stroke risk and NSAIDs: a systematic review of observational studies

21 January 2018

1 reference

Identifying potential adverse events dose-response relationships via Bayesian indirect and mixed treatment comparison models

21 January 2018

1 reference

The strengths and limitations of meta-analyses based on aggregate data

21 January 2018

1 reference

Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions

21 January 2018

1 reference

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

21 January 2018

1 reference

Checking consistency in mixed treatment comparison meta-analysis

21 January 2018

1 reference

Bayesian statistics in medical devices: innovation sparked by the FDA.

21 January 2018

1 reference

Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting.

21 January 2018

1 reference

Bayesian methods for design and analysis of safety trials.

21 January 2018

1 reference

Bayesian hierarchical modeling for detecting safety signals in clinical trials

21 January 2018

1 reference

Conflict Diagnostics in Directed Acyclic Graphs, with Applications in Bayesian Evidence Synthesis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PST.1592

1 reference

22 December 2017

1 reference

22 December 2017